Emerging Company in the Spotlight sponsored by JFK Communications.
Congratulations to Cancer Genetics, BioNJ’s Emerging Company in the Spotlight for August. Each month we will feature a BioNJ Member who is progressively growing and evolving within the New Jersey biotechnology industry. So many of our Members are making a dramatic impact on our State’s innovative ecosystem. And, for that we say thank you.
Cancer Genetics, Inc. (CGI) is an emerging leader in the field of oncology diagnostics, specializing in personalized medicine. Over the past few years, CGI, based in Rutherford, NJ, has transformed from a locally known reference laboratory into a global leader in the oncology diagnostics market serving the clinical and biopharma communities, with locations in the U.S., India and China. CGI works with seven out of ten of the biggest pharmaceutical companies worldwide through its clinical trial services, Select One®.
Guided by the mission to be the leading oncology diagnostics partner from bench to bedside, the company offers a wide array of products that differentiate CGI from its competitors. These offerings include disease-specific genomic testing panels, comprehensive clinical laboratory testing and the ability to maintain a cycle of innovation, which enables CGI to update technologies and test algorithms for its proprietary tests.
Through research collaborations with major cancer centers, CGI exemplifies a devotion to innovation through its flagship diagnostic testing products:
• CGI’s Focus::NGS™ panels utilize next-generation sequencing (NGS) to provide mutation analysis for a number of hematological malignancies.
• Mature B-cell Neoplasm Array (MATBA®) tests use array-CGH (comparative genomic hybridization) technology to detect chromosomal changes that have value for the diagnosis and prognosis of non-Hodgkin lymphomas and leukemias.
• CGI’s FISH-based HPV-Associated Cancer Test (FHACT®), available for cervical cancer, is a non-invasive test that detects chromosomal changes associated with pre-cancerous and cancerous lesions. FHACT® can help clinicians determine whether a woman is likely to have advanced cervical disease before performing more invasive testing.
• CGI’s proprietary Urogenital Cancer Array (UroGenRA®-Kidney) is designed to diagnose and subtype kidney cancer, which is critical to determining the best treatment for each patient. Because UroGenRA® can be performed using core needle biopsy specimens, full or partial nephrectomy may be avoided for patients with less aggressive or benign disease.
In addition to CGI’s flagship products, the company has a number of NGS panels in the pipeline intended for lymphomas, kidney cancer and comprehensive pharmacogenomics. Through its joint venture with Mayo Clinic, OncoSpire Genomics, the company is also working on NGS panels for multiple myeloma, follicular lymphoma and lung cancer.
“By leveraging our state-of-the-art reference laboratories, CGI can deliver accurate, reliable and comprehensive biomarker assessment for patient stratification and randomization purposes,” said Dr. Narasimha Marella, Corporate Development Manager at CGI. “CGI has developed a number of proprietary assays in hematological as well as in solid tumors, and the strength in our Select One® program lays in the ability to offer a disease-focused suite of proprietary and non-proprietary tests that deliver diagnostic, prognostic and theranostic value.”
Beyond CGI’s unique product offerings, the company’s high regard for its own people and its community is a factor that truly differentiates it from competitors. CGI’s corporate culture is centered around shared equity and giving back to the community. The company aims to ensure that each employee feels like a part of the company by ensuring that all employees have the opportunity to be invested as stockholders. Valuing transparency and the possibility for innovation at every level, CGI encourages employees to be engaged with the company through active feedback and collaboration. CGI regularly hosts company-wide meetings to keep employees abreast of its pipelines and business. These meetings provide an ideal forum for the generation of feedback and new ideas.
CGI also encourages company-wide participation in philanthropic events to support cancer survivors and their families. Each year the company participates in a number of fundraisers to support non-profit cancer advocacy foundations.
CGI is focused on delivering products and services that drive the highest levels of patient value. To achieve this, the company has developed a corporate culture that inspires innovation, respects knowledge and fosters leadership. Its dedicated staff takes pride in its specialized laboratory services, superior turnaround time, enhanced reporting, and ongoing research and development for new tests. CGI’s full-service cancer genetic practice and path to innovation with research fosters optimal patient care management.
“CGI is perfectly positioned to be a one-stop solution and a unique partner for all oncology-focused clinical trials,” added Dr. Marella.